Cryoport, Inc. Recognized as Finalist in Life Science Sales & Marketing Awards
October 30, 2024 – Cryoport, Inc., a global leader in temperature-controlled supply chain solutions for the life sciences industry, is proud to announce its recognition as a finalist in two prestigious categories of the Life Science Sales & Marketing Awards: Marketing Team of the Year and Campaign of the Year for the Enabling the Future of Medicine™ rebranding campaign.
Winners Announced!
Cryoport is honored to announce that we have been selected as the Winners in the category of Marketing Team of the Year! Let’s make a difference, together as Cryoport Systems continues to lead the way, Enabling the Outcome™ for cell and gene therapy innovation!
Celebrating Excellence in Life Sciences
Established by six visionary doctors, Cryoport, Inc. has transformed from its original mission of developing a more stable dry-ice packaging solution to become a comprehensive network that supports all facets of the temperature-sensitive supply chain. Our diverse business units—including Cryoport Systems, CRYOGENE, CRYOPDP, and MVE Biological Solutions—deliver critical services and products in logistics, biostorage, cryopreservation, and consulting to the biopharmaceutical, reproductive medicine, and animal health industries.
Our marketing teams play a vital role in this transformation, developing campaigns that highlight our innovative solutions and commitment to maintaining the integrity and viability of sensitive materials. In the past year, our collaborative approach has garnered significant industry attention, leading to increased brand awareness and recognition in life science publications.
The Power of Rebranding
The past year has been marked by significant advancements for Cryoport, Inc., most notably through our comprehensive rebranding effort launched in January 2024. This initiative unified our four business units under one cohesive identity, enhancing our ability to communicate our integrative supply chain management capabilities to a global audience.
Our marketing teams faced unique challenges during this rebranding process, including navigating different time zones and cultural nuances to ensure our messaging resonated with clients worldwide. With a simultaneous launch at Phacilitate’s Advanced Therapies Week and Nasdaq MarketSite, we successfully unveiled our new logo and tagline, “Enabling the Future of Medicine™,” symbolizing our dedication to supporting lifesaving therapies through our enhanced supply chain solutions.
Achievements That Matter
The results of our efforts have been tangible. The rebranding campaign has positioned Cryoport, Inc. as a leading authority in temperature-sensitive supply chain solutions, now supporting over 675 clinical trials and more than 15 commercial therapies. This recognition has strengthened partnerships with like-minded organizations and elevated our standing within the life sciences community.
Our marketing teams have shown exceptional creativity and dedication, leveraging their diverse skill sets to deliver impactful campaigns that drive engagement and reinforce our commitment to excellence. Their efforts have resulted in an increase in social media followings and significant media coverage, highlighting Cryoport, Inc. as a trusted partner in the life sciences industry.
A Bright Future Ahead
As we celebrate this achievement, we remain committed to our mission of Enabling the Future of Medicine™ for our clients. The recognition as finalists in the Life Science Sales & Marketing Awards underscores our relentless pursuit of excellence and innovation in the life sciences supply chain.
Cryoport, Inc. looks forward to continuing to support the industry with our safe, compliant, and innovative solutions—empowering certainty for the life sciences, one patient, one therapy, and one product at a time.
Thank you for being part of our journey!